10-Q: Certara, Inc. Reports Third Quarter 2024 Results, Revenue Up 11% Year-Over-Year

Certara, Inc. announced its financial results for the third quarter of 2024, showing an 11% increase in total revenue compared to the same period last year.

Summary

• Certara, Inc. reported a total revenue of $94.8 million for the third quarter of 2024, an 11% increase compared to $85.6 million in the third quarter of 2023.
• Software revenue increased by 15% to $35.9 million, while service revenue grew by 9% to $58.9 million.
• The company experienced a net loss of $1.4 million for the quarter, a significant improvement from the $49.0 million net loss in the same quarter of the previous year.
• Adjusted EBITDA for the quarter was $33.1 million, compared to $28.8 million in the third quarter of 2023.
• For the nine months ended September 30, 2024, total revenue was $284.8 million, a 7% increase from $266.3 million in the same period of 2023.
• The net loss for the first nine months of 2024 was $18.6 million, compared to a net loss of $42.9 million for the same period in 2023.
• The company's net retention rate for software customers was 107.6% for the third quarter of 2024.
• The company completed three acquisitions since the beginning of 2023: Drug Interaction Solutions (DIDB), Formedix Limited, and Applied BioMath, LLC (ABM).

Sentiment

Score: 7

Explanation: The document shows positive trends in revenue growth and improved profitability, but the company is still operating at a loss. The strategic acquisitions and investments in growth are promising, but there are also risks related to competition and macroeconomic conditions. Overall, the sentiment is cautiously optimistic.

Positives

• The company experienced strong revenue growth in both software and services.
• There was a significant improvement in net loss compared to the previous year.
• Adjusted EBITDA increased year-over-year, indicating improved operational performance.
• The company's net software retention rate remains strong, showing customer loyalty.
• The company has successfully completed several strategic acquisitions to expand its offerings.

Negatives

• The company still reported a net loss for the quarter and the nine-month period, although significantly reduced from the previous year.
• Operating expenses, particularly sales and marketing, have increased significantly.
• The company has incurred significant costs related to acquisitions and integration.

Risks

• The company's future performance depends on its ability to retain and expand its customer base.
• Changes in government regulations could impact the demand for the company's products and services.
• The company faces competition in the biosimulation market.
• Uncertain macroeconomic conditions could pose challenges to the business.
• The company's ability to integrate acquisitions successfully is crucial for future growth.

Future Outlook

The company expects to continue investing in growth, including expanding its solutions, acquisitions, and international expansion. They anticipate that AI and machine learning will continue to enhance the accuracy and usefulness of biosimulation models.

Management Comments

• Management believes that the company's existing sources of liquidity will be sufficient to meet its working capital, capital expenditures, and contractual obligations for the foreseeable future.
• Management measures operating performance based on adjusted EBITDA and adjusted net income to assess the performance of the business.

Industry Context

The company operates in the biopharmaceutical industry, where model-informed drug development is increasingly being adopted. The company's solutions are used by life sciences companies and regulatory agencies, and the company is leveraging AI and machine learning to enhance its offerings. The industry is highly regulated, and changes in regulations can impact the demand for the company's products and services.

Comparison to Industry Standards

• Certara's revenue growth of 11% in Q3 2024 is a positive sign, indicating a strong demand for its biosimulation products and services. This growth rate is comparable to other companies in the life sciences technology sector, such as Veeva Systems, which reported a 16% year-over-year revenue growth in its most recent quarter.
• The company's adjusted EBITDA of $33.1 million in Q3 2024, while an improvement from the previous year, is still lower than some of its larger competitors. For example, companies like Medidata Solutions, a Dassault Systèmes company, typically report higher EBITDA margins due to their scale and established market presence.
• Certara's net loss of $1.4 million in Q3 2024, while a significant improvement, highlights the challenges of achieving profitability in a competitive market. Other companies in the sector, such as Schrodinger, have also reported net losses, indicating that profitability is a common challenge in the early stages of growth.
• The company's net software retention rate of 107.6% is a strong indicator of customer loyalty and satisfaction. This rate is comparable to industry benchmarks for SaaS companies, where a retention rate above 100% is considered healthy.
• Certara's strategic acquisitions, such as DIDB, Formedix, and ABM, are in line with industry trends of consolidation and expansion of product offerings. These acquisitions are similar to moves made by other companies in the sector to enhance their capabilities and market reach.

Stakeholder Impact

• Shareholders will be encouraged by the improved financial performance and strategic acquisitions.
• Employees may benefit from the company's growth and investments in talent.
• Customers will have access to a broader range of solutions and services.
• Suppliers and creditors will be impacted by the company's financial performance and ability to meet its obligations.

Next Steps

• The company will finalize the initial accounting for the acquisition of Chemaxon in the fourth quarter of 2024.
• The company will continue to assess the probability of achieving performance thresholds for performance stock units at each reporting period.

Key Dates

Keywords

biosimulation, model-informed drug development, software licenses, SaaS, professional services, revenue growth, EBITDA, acquisitions, net loss, regulatory science